Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase I/II Open Label Multi-center Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients with Advanced Malignancies

A Phase I/II Open Label Multi-center Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients with Advanced Malignancies

18 years - 99 years
All genders
Phase 1
The purpose of this study is to help define the proper dose amounts, safety and benefits of AMXI-5001 in participants 18 years and older, who have the disease which the study drug may treat, for example, cancer. This study is the first time AMXI-5001 has been given to people. We …
Learn More
Fusion - FPX-01-01

Fusion - FPX-01-01

18 years - 99 years
All genders
Phase 1
A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 …
Learn More
COMPPARE

COMPPARE

30 years - 80 years
All genders
This study is a comparison of patient-centric outcomes between parallel cohorts of men with prostate cancer treated using intensity-modulated radiation therapy techniques. This study includes a pre-specified randomized comparison of standard fractionation and moderate hypofractionation dose schemes within the proton therapy cohort. In addition, subgroup analyses will include a comparison …
Learn More
MG0004: A randomized open-label extension study to investigate the long-term safety tolerability and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis

MG0004: A randomized open-label extension study to investigate the long-term safety tolerability and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis

99 years or below
All genders
Phase 3
Rozanolixizumab is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of the activity of the neonatal Fc receptor (FcRn) for IgG. By blocking the activity of neonatal FcRn, rozanolixizumab accelerates the catabolism of antibodies and reduces the serum IgG concentration, including pathogenic IgG in MG patients, …
Learn More
CILT + HD-tDCS as a Potential Treatment for Primary Progressive Aphasia

CILT + HD-tDCS as a Potential Treatment for Primary Progressive Aphasia

45 years - 80 years
All genders
Phase 2
Primary Progressive Aphasia, or PPA, is a neurodegenerative disease that affects language abilities. A person with PPA may have difficulties speaking, understanding speech, reading, or writing, and these difficulties worsen over time.The purpose of this study is to determine whether a form of non-invasive brain stimulation called High-definition Transcranial Direct …
Learn More

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY)

99 years or below
All genders
This is a prospective, observational study that will enroll 8000 patients with acute-onset ischemic stroke, intracerebral hemorrhage or aneurysmal subarchnoid hemorrhage within 6 weeks of onset. Participants will undergo both in person and telephone follow up in order to assess for longitudinal cognitive and functional outcomes.
Learn More
TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

18 years - 99 years
All genders
Phase 1
Interventional
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell …
Learn More
A Phase 1 Study of IL-15 Superagonist (N-803) and Broadly Neutralizing Antibodies to Induce HIV-1 Control

A Phase 1 Study of IL-15 Superagonist (N-803) and Broadly Neutralizing Antibodies to Induce HIV-1 Control

18 years - 70 years
All genders
Phase 1
This study will investigate whether N-803, a new experimental drug that stimulates the immune system, is safe and tolerable when given alone and in combination with two new experimental drugs that are antibodies (natural proteins that the body makes in response to an infection) to HIV (the virus that causes …
Check Eligibility
A Phase 3 Prospective Multi-Center Single-Arm Open-Label Study to Evaluate VeraCept a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy Safety and Tolerability

A Phase 3 Prospective Multi-Center Single-Arm Open-Label Study to Evaluate VeraCept a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy Safety and Tolerability

18 years - 45 years
Accepts healthy volunteer
Female
Phase 3
A research study for woman of child bearing age or potential and interested in using an intrauterine device (IUD) for birth control for up to 5 years.
Learn More
A multicenter double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

A multicenter double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

18 years - 100 years
All genders
Phase 3
Interventional
The purpose of this study is to find out if the investigational drug, apraglutide and investigational drug , is able to reduce the volume per week of PS required in adults with short bowel syndrome and intestinal failure.
Learn More
401 - 410 of 1243